CD8A and liver cancer: Oxaliplatin, a prevalent chemotherapy drug, has been found to elevate ICD biomarkers in liver cancer cells and, in vivo, to increase mature DCs and CD8+ T cells while decreasing regulatory T (Treg) cells.